Spironolactone and Gynecomastia: Is It a Common Side Effect?

Spironolactone is prescribed for a wide range of conditions — heart failure, hypertension, primary hyperaldosteronism, and increasingly as an off-label treatment for acne and hormonal skin issues in men. It works well for all of those things. It also has one of the strongest and most documented links to drug-induced gynecomastia of any medication currently in common use. How common that side effect actually is depends heavily on the dose, and it's something we think every man starting spironolactone should understand before he begins.

Table of Contents

What Is Spironolactone and Why Does It Cause Gynecomastia?

Spironolactone is an aldosterone antagonist, originally developed to treat fluid retention and high blood pressure by blocking the mineralocorticoid receptor in the kidney. But it isn’t selective. It also acts on androgen and estrogen receptors throughout the body, and that’s where the problem starts.

The mechanism isn’t a single pathway — it’s several working simultaneously. Research published in the Annals of Internal Medicine demonstrated that spironolactone significantly lowers blood testosterone levels while raising estradiol, primarily by increasing the rate at which testosterone is peripherally converted to estradiol and accelerating testosterone’s metabolic clearance. The estrogen-to-androgen ratio shifts in a direction that directly promotes breast tissue development.

Beyond that hormonal shift, spironolactone also blocks androgen receptors directly, preventing testosterone and dihydrotestosterone from binding and exerting their normal inhibitory effect on breast tissue. It inhibits enzymes in the testosterone synthesis pathway, displaces testosterone from sex hormone-binding globulin, and increases free estradiol in circulation. The result is a drug that hits the estrogen-androgen balance from multiple directions at once, which is why its association with gynecomastia is so well established.

How Common Is It?

More common than most men are told when the prescription is written.

The numbers vary by dose, but they’re not small. Data from the RALES trial — the landmark study of spironolactone in heart failure patients — reported gynecomastia or breast discomfort in 10% of men taking the drug as part of standard therapy. That’s the figure most often cited for typical clinical doses. At higher doses, the picture gets significantly worse. Studies using doses of 150mg per day have reported incidence rates of up to 52%. A controlled study in normal males found gynecomastia in 30% of the low-dose group and 62% of the high-dose group after ten months of treatment, with zero cases in the placebo group.

For context, that puts spironolactone in a different category from most drugs associated with gynecomastia. The link isn’t incidental or poorly understood — it’s dose-dependent, mechanistically clear, and consistent across multiple studies spanning decades.

Does Dose Actually Matter That Much?

Yes, substantially. The relationship between spironolactone dose and gynecomastia risk is one of the more clearly documented dose-response relationships in drug-induced gynecomastia.

Men taking low doses for acne or mild hypertension — often in the range of 25 to 50mg daily — face meaningfully lower risk than men on 100 to 200mg for heart failure or resistant hypertension. But low risk isn’t no risk. Gynecomastia has been documented at doses below 50mg, and individual sensitivity varies enough that some men develop significant breast tissue development at doses that cause no problem at all in others.

Duration of treatment also compounds dose. A man on 25mg for six months faces a different cumulative exposure than one who has been on the same dose for five years. The longer the exposure, the more opportunity for glandular tissue to establish itself and fibrose

What Does Spironolactone Gynecomastia Look and Feel Like?

It typically presents as bilateral breast enlargement, often with tenderness or sensitivity in the nipple-areola complex. Tenderness is actually a useful early signal — it suggests the tissue is still in the active proliferative phase rather than fibrosed, which matters for management options.

Unilateral presentation is less common but documented. It can be mistaken for a breast lump of other origin, which is one reason any new breast tissue development in a man on spironolactone warrants clinical evaluation rather than self-monitoring alone.

Onset varies. Some men notice changes within a few months of starting the drug. Others develop gynecomastia after years of stable use, particularly if the dose is increased or other hormonal factors shift.

What Happens If You Stop Taking It?

Discontinuing spironolactone removes the hormonal driver, and for cases caught early — typically within the first year, while the tissue is still active rather than fibrosed — stopping the drug often leads to meaningful improvement or full resolution. The case series and clinical reports consistently show that early discontinuation is the most reliable path to reversal.

For men who’ve been on the drug for longer, or where the tissue has become firm and established, stopping spironolactone stabilizes the situation but doesn’t reverse it. Fibrosed glandular tissue doesn’t regress regardless of what happens to the hormonal environment afterward. That’s the same principle that applies to gynecomastia from any cause — the tissue window for medical management is finite.

What If You Can't Stop Taking It?

Some men are on spironolactone for conditions where stopping isn’t straightforward. Heart failure patients in particular often depend on it as part of a medication regimen that’s managing a serious condition. In those situations, a few alternatives are worth discussing with the prescribing physician.

Eplerenone is a newer, more selective aldosterone antagonist that doesn’t carry the same anti-androgenic activity as spironolactone. It has documented efficacy for heart failure and hypertension and a significantly lower incidence of gynecomastia. The main drawback is cost — it’s considerably more expensive than spironolactone and may not be covered equally depending on insurance. For men who develop gynecomastia on spironolactone and need to stay on an aldosterone antagonist, switching to eplerenone is the most commonly recommended approach.

If switching isn’t possible and gynecomastia is causing significant discomfort or psychological distress, SERM therapy — tamoxifen or raloxifene — can be considered during the active tissue phase. As with all medical management of gynecomastia, the window is limited and the results are incomplete for established tissue.

When Surgery Becomes the Relevant Conversation

Men who’ve been on spironolactone for years and developed established gynecomastia often come to us after having tried discontinuing the drug or switching medications without the tissue resolving. At that point, the tissue is structural. It’s fibrosed, it’s not going away on its own, and medical management isn’t going to change that.

We see this presentation regularly at Regeneris — men who were never told the risk was this concrete, who didn’t connect what they noticed in their chest to a blood pressure medication they’ve been taking for years. The conversation is straightforward once they understand what they’re dealing with. If you’ve developed gynecomastia on spironolactone and want to understand your options, you can learn more about chest reduction surgery for gynecomastia in Boston and what the correction process involves.

Peak Masculinity
Starts Here

By Dr. Ryan Welter

March 10, 2026

The Best Version
of You Starts Here

Schedule a consultation with Dr. Ryan Welter